Unlike small molecule generics, …biosimilars that are approved by the USFDA need to be promoted under brands and are not interchangeable for innovators’ brand prescriptions…the USFDA issued guidelines …have raised the entry barrier for biosimilar players…Unless biosimilar are interchangeable, they remain prone to competition from biobetters.